Intracellular ABCB1 as a Possible Mechanism to Explain the Synergistic Effect of Hydroxychloroquine-Azithromycin Combination in COVID-19 Therapy

DOI record: { "DOI": "10.1208/s12248-020-00465-w", "ISSN": [ "1550-7416" ], "URL": "http://dx.doi.org/10.1208/s12248-020-00465-w", "alternative-id": [ "465" ], "article-number": "86", "assertion": [ { "group": { "label": "Article History", "name": "ArticleHistory" }, "label": "Received", "name": "received", "order": 1, "value": "17 April 2020" }, { "group": { "label": "Article History", "name": "ArticleHistory" }, "label": "Accepted", "name": "accepted", "order": 2, "value": "19 May 2020" }, { "group": { "label": "Article History", "name": "ArticleHistory" }, "label": "First Online", "name": "first_online", "order": 3, "value": "12 June 2020" }, { "group": { "label": "Compliance with Ethical Standards", "name": "EthicsHeading" }, "name": "Ethics", "order": 1 }, { "group": { "label": "Conflict of Interest", "name": "EthicsHeading" }, "name": "Ethics", "order": 2, "value": "The author declares that he has no conflict of interest." }, { "label": "Free to read", "name": "free", "value": "This content has been made available to all." } ], "author": [ { "affiliation": [], "family": "Scherrmann", "given": "JM.", "sequence": "first" } ], "container-title": "The AAPS Journal", "container-title-short": "AAPS J", "content-domain": { "crossmark-restriction": false, "domain": [ "link.springer.com" ] }, "created": { "date-parts": [ [ 2020, 6, 12 ] ], "date-time": "2020-06-12T16:02:59Z", "timestamp": 1591977779000 }, "deposited": { "date-parts": [ [ 2022, 10, 28 ] ], "date-time": "2022-10-28T03:09:57Z", "timestamp": 1666926597000 }, "indexed": { "date-parts": [ [ 2024, 3, 6 ] ], "date-time": "2024-03-06T07:46:02Z", "timestamp": 1709711162994 }, "is-referenced-by-count": 23, "issue": "4", "issued": { "date-parts": [ [ 2020, 6, 12 ] ] }, "journal-issue": { "issue": "4", "published-print": { "date-parts": [ [ 2020, 7 ] ] } }, "language": "en", "license": [ { "URL": "https://www.springer.com/tdm", "content-version": "tdm", "delay-in-days": 0, "start": { "date-parts": [ [ 2020, 6, 12 ] ], "date-time": "2020-06-12T00:00:00Z", "timestamp": 1591920000000 } }, { "URL": "https://www.springer.com/tdm", "content-version": "vor", "delay-in-days": 0, "start": { "date-parts": [ [ 2020, 6, 12 ] ], "date-time": "2020-06-12T00:00:00Z", "timestamp": 1591920000000 } } ], "link": [ { "URL": "https://link.springer.com/content/pdf/10.1208/s12248-020-00465-w.pdf", "content-type": "application/pdf", "content-version": "vor", "intended-application": "text-mining" }, { "URL": "https://link.springer.com/article/10.1208/s12248-020-00465-w/fulltext.html", "content-type": "text/html", "content-version": "vor", "intended-application": "text-mining" }, { "URL": "https://link.springer.com/content/pdf/10.1208/s12248-020-00465-w.pdf", "content-type": "application/pdf", "content-version": "vor", "intended-application": "similarity-checking" } ], "member": "297", "original-title": [], "prefix": "10.1208", "published": { "date-parts": [ [ 2020, 6, 12 ] ] }, "published-online": { "date-parts": [ [ 2020, 6, 12 ] ] }, "published-print": { "date-parts": [ [ 2020, 7 ] ] }, "publisher": "Springer Science and Business Media LLC", "reference": [ { "DOI": "10.1016/j.ijantimicag.2020.105949", "doi-asserted-by": "publisher", "key": "465_CR1", "unstructured": "Gautret P, Lagier JC, Parola P, Hoang VT, Meddeb L, Mailhe M, et al. Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial. Int J Antimicrob Agents. 2020. https://doi.org/10.1016/j.ijantimicag.2020.105949." }, { "author": "J Chen", "first-page": "0", "issue": "1", "journal-title": "J Zhejiang Univ (Med Sci)", "key": "465_CR2", "unstructured": "Chen J, Liu L, Liu P, Xu Q, Xia L, Ling Y, et al. A pilot study of hydroxychloroquine in treatment of patients with common coronavirus disease-19 (COVID-19). J Zhejiang Univ (Med Sci). 2020;49(1):0.", "volume": "49", "year": "2020" }, { "DOI": "10.5582/bst.2020.01047", "author": "J Gao", "doi-asserted-by": "publisher", "first-page": "72", "issue": "1", "journal-title": "Biosci Trends", "key": "465_CR3", "unstructured": "Gao J, Tian Z, Yang X. Breakthrough: chloroquine phosphate has shown apparent efficacy in treatment of COVID-19 associated pneumonia in clinical studies. Biosci Trends. 2020;14(1):72–3.", "volume": "14", "year": "2020" }, { "DOI": "10.1093/jac/dkaa114", "doi-asserted-by": "publisher", "key": "465_CR4", "unstructured": "Zhou D, Dai SM, Tong Q. COVID-19: a recommendation to examine the effect of hydroxychloroquine in preventing infection and progression. J Antimicrob Chemother. 2020. https://doi.org/10.1093/jac/dkaa114." }, { "DOI": "10.3399/bjgpopen20X101069", "doi-asserted-by": "publisher", "key": "465_CR5", "unstructured": "Gbinigie K, Frie K. Should chloroquine and hydroxychloroquine be used to treat COVID-19? A rapid review. BJGP Open. 2020. https://doi.org/10.3399/bjgpopen20X101069." }, { "DOI": "10.4269/ajtmh.20-0230", "author": "M Keshtkar-Jahromi", "doi-asserted-by": "publisher", "first-page": "932", "journal-title": "Am J Trop Med Hyg", "key": "465_CR6", "unstructured": "Keshtkar-Jahromi M, Bavari S. A call for randomized controlled trials to test the efficacy of chloroquine and hydroxychloroquine as therapeutics against novel coronavirus disease (COVID-19). Am J Trop Med Hyg. 2020;102:932–3.", "volume": "102", "year": "2020" }, { "DOI": "10.5582/bst.2020.03058", "doi-asserted-by": "publisher", "key": "465_CR7", "unstructured": "Ohe M, Shida H, Jodo S, Kusunoki Y, Seki M, Furuya K, et al. Macrolide treatment for COVID-19: will this be the way forward? Biosci Trends. 2020;14(2):159–60. https://doi.org/10.5582/bst.2020.03058." }, { "DOI": "10.1002/cpt.1857", "doi-asserted-by": "publisher", "key": "465_CR8", "unstructured": "Damle B, Vourvahis M, Wang E, Leaney J, Corrigan B. Clinical pharmacology perspectives on the antiviral activity of azithromycin and use in COVID-19. Clin Pharmacol Ther. 2020. https://doi.org/10.1002/cpt.1857." }, { "DOI": "10.1016/j.ijantimicag.2020.105938", "doi-asserted-by": "publisher", "key": "465_CR9", "unstructured": "Devaux CA, Rolain JM, Colson P, Raoult D. New insights on the antiviral effects of chloroquine against coronavirus: what to expect for COVID-19? Int J Antimicrob Agents. 2020;55(5):105938. https://doi.org/10.1016/j.ijantimicag.2020.105938." }, { "DOI": "10.4269/ajtmh.1992.47.378", "author": "BA Gingras", "doi-asserted-by": "publisher", "first-page": "378", "issue": "3", "journal-title": "Am J Trop Med Hyg", "key": "465_CR10", "unstructured": "Gingras BA, Jensen JB. Activity of azithromycin (CP-62,993) and erythromycin against chloroquine-sensitive and chloroquine-resistant strains of plasmodium falciparum in vitro. Am J Trop Med Hyg. 1992;47(3):378–82.", "volume": "47", "year": "1992" }, { "author": "NA Kshirsagar", "first-page": "85", "journal-title": "Res Rep Trop Med", "key": "465_CR11", "unstructured": "Kshirsagar NA, Gogtay NJ, Moran D, Utz G, Sethia A, Sarkar S, et al. Treatment of adults with acute uncomplicated malaria with azithromycin and chloroquine in India, Colombia, and Suriname. Res Rep Trop Med. 2017;8:85–104.", "volume": "8", "year": "2017" }, { "DOI": "10.1128/AAC.01566-10", "author": "MR Pereira", "doi-asserted-by": "publisher", "first-page": "3115", "issue": "7", "journal-title": "Antimicrob Agents Chemother", "key": "465_CR12", "unstructured": "Pereira MR, Henrich PP, Sidhu AB, Johnson D, Hardink J, Van Deusen J, et al. In vivo and in vitro antimalarial properties of azithromycin-chloroquine combinations that include the resistance reversal agent amlodipine. Antimicrob Agents Chemother. 2011;55(7):3115–24.", "volume": "55", "year": "2011" }, { "author": "S Dey", "first-page": "29", "journal-title": "J Inflamm Res", "key": "465_CR13", "unstructured": "Dey S, Bishayi B. Killing of Staphylococcus aureus in murine macrophages by chloroquine used alone and in combination with ciprofloxacin or azithromycin. J Inflamm Res. 2015;8:29–47.", "volume": "8", "year": "2015" }, { "DOI": "10.1002/prp2.293", "author": "MAA Al-Bari", "doi-asserted-by": "publisher", "first-page": "e00293", "issue": "1", "journal-title": "Pharmacol Res Perspect", "key": "465_CR14", "unstructured": "Al-Bari MAA. Targeting endosomal acidification by chloroquine analogs as a promising strategy for the treatment of emerging viral diseases. Pharmacol Res Perspect. 2017;5(1):e00293.", "volume": "5", "year": "2017" }, { "DOI": "10.1016/S1473-3099(11)70092-5", "author": "A Savarino", "doi-asserted-by": "publisher", "first-page": "653", "issue": "9", "journal-title": "Lancet Infect Dis", "key": "465_CR15", "unstructured": "Savarino A. Use of chloroquine in viral diseases. Lancet Infect Dis. 2011;11(9):653–4.", "volume": "11", "year": "2011" }, { "DOI": "10.1021/acsinfecdis.5b00030", "author": "PB Madrid", "doi-asserted-by": "publisher", "first-page": "317", "issue": "7", "journal-title": "ACS Infect Dis", "key": "465_CR16", "unstructured": "Madrid PB, Panchal RG, Warren TK, Shurtleff AC, Endsley AN, Green CE, et al. Evaluation of Ebola virus inhibitors for drug repurposing. ACS Infect Dis. 2015;1(7):317–26.", "volume": "1", "year": "2015" }, { "DOI": "10.1016/S1473-3099(03)00806-5", "author": "A Savarino", "doi-asserted-by": "publisher", "first-page": "722", "issue": "11", "journal-title": "Lancet Infect Dis", "key": "465_CR17", "unstructured": "Savarino A, Boelaert JR, Cassone A, Majori G, Cauda R. Effects of chloroquine on viral infections: an old drug against today’s diseases? Lancet Infect Dis. 2003;3(11):722–7.", "volume": "3", "year": "2003" }, { "DOI": "10.1016/j.antiviral.2017.11.017", "author": "YW Tan", "doi-asserted-by": "publisher", "first-page": "143", "journal-title": "Antiviral Res", "key": "465_CR18", "unstructured": "Tan YW, Yam WK, Sun J, Chu JJH. An evaluation of chloroquine as a broad-acting antiviral against hand, Foot and Mouth Disease. Antiviral Res. 2018;149:143–9.", "volume": "149", "year": "2018" }, { "DOI": "10.1038/s41422-020-0282-0", "author": "M Wang", "doi-asserted-by": "publisher", "first-page": "269", "issue": "3", "journal-title": "Cell Res", "key": "465_CR19", "unstructured": "Wang M, Cao R, Zhang L, Yang X, Liu J, Xu M, et al. Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro. Cell Res. 2020;30(3):269–71.", "volume": "30", "year": "2020" }, { "DOI": "10.1038/s41421-020-0156-0", "author": "J Liu", "doi-asserted-by": "publisher", "first-page": "16", "journal-title": "Cell Discov", "key": "465_CR20", "unstructured": "Liu J, Cao R, Xu M, Wang X, Zhang H, Hu H, et al. Hydroxychloroquine, a less toxic derivative of chloroquine, is effective in inhibiting SARS-CoV-2 infection in vitro. Cell Discov. 2020;6:16.", "volume": "6", "year": "2020" }, { "DOI": "10.1093/cid/ciaa237", "doi-asserted-by": "publisher", "key": "465_CR21", "unstructured": "Yao X, Ye F, Zhang M, Cui C, Huang B, Niu P, et al. In vitro antiviral activity and projection of optimized dosing design of hydroxychloroquine for the treatment of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Clin Infect Dis. 2020. https://doi.org/10.1093/cid/ciaa237." }, { "DOI": "10.1002/cpt.1856", "doi-asserted-by": "publisher", "key": "465_CR22", "unstructured": "Garcia-Cremades M, Solans BP, Hughes E, Ernest JP, Wallender E, Aweeka F, et al. Optimizing hydroxychloroquine dosing for patients with COVID-19: an integrative modeling approach for effective drug repurposing. Clin Pharmacol Ther. 2020. https://doi.org/10.1002/cpt.1856." }, { "DOI": "10.1038/s41573-019-0036-1", "author": "SR Bonam", "doi-asserted-by": "publisher", "first-page": "923", "issue": "12", "journal-title": "Nat Rev Drug Discov", "key": "465_CR23", "unstructured": "Bonam SR, Wang F, Muller S. Lysosomes as a therapeutic target. Nat Rev Drug Discov. 2019;18(12):923–48.", "volume": "18", "year": "2019" }, { "DOI": "10.1177/0961203317727601", "author": "H Al-Rawi", "doi-asserted-by": "publisher", "first-page": "847", "issue": "5", "journal-title": "Lupus.", "key": "465_CR24", "unstructured": "Al-Rawi H, Meggitt SJ, Williams FM, Wahie S. Steady-state pharmacokinetics of hydroxychloroquine in patients with cutaneous lupus erythematosus. Lupus. 2018;27(5):847–52.", "volume": "27", "year": "2018" }, { "DOI": "10.1517/17425255.2011.598506", "author": "RM Chico", "doi-asserted-by": "publisher", "first-page": "1153", "issue": "9", "journal-title": "Expert Opin Drug Metab Toxicol", "key": "465_CR25", "unstructured": "Chico RM, Chandramohan D. Azithromycin plus chloroquine: combination therapy for protection against malaria and sexually transmitted infections in pregnancy. Expert Opin Drug Metab Toxicol. 2011;7(9):1153–67.", "volume": "7", "year": "2011" }, { "DOI": "10.1128/AAC.02430-12", "author": "T Pene Dumitrescu", "doi-asserted-by": "publisher", "first-page": "3194", "issue": "7", "journal-title": "Antimicrob Agents Chemother", "key": "465_CR26", "unstructured": "Pene Dumitrescu T, Anic-Milic T, Oreskovic K, Padovan J, Brouwer KL, Zuo P, et al. Development of a population pharmacokinetic model to describe azithromycin whole-blood and plasma concentrations over time in healthy subjects. Antimicrob Agents Chemother. 2013;57(7):3194–201.", "volume": "57", "year": "2013" }, { "DOI": "10.1101/2020.03.29.008631", "doi-asserted-by": "publisher", "key": "465_CR27", "unstructured": "Poschet JF, Perkett EA, Timmins GS, Deretic V. Azithromycin and ciprofloxacin have a chloroquine-like effect on respiratory epithelial cells. bioRxiv. 2020. https://doi.org/10.1101/2020.03.29.008631." }, { "DOI": "10.1021/mp200641e", "author": "RS Funk", "doi-asserted-by": "publisher", "first-page": "1384", "issue": "5", "journal-title": "Mol Pharm", "key": "465_CR28", "unstructured": "Funk RS, Krise JP. Cationic amphiphilic drugs cause a marked expansion of apparent lysosomal volume: implications for an intracellular distribution-based drug interaction. Mol Pharm. 2012;9(5):1384–95.", "volume": "9", "year": "2012" }, { "DOI": "10.1124/mol.118.113118", "author": "J Sironi", "doi-asserted-by": "publisher", "first-page": "127", "issue": "1", "journal-title": "Mol Pharmacol", "key": "465_CR29", "unstructured": "Sironi J, Aranda E, Nordstrom LU, Schwartz EL. Lysosome membrane permeabilization and disruption of the molecular target of rapamycin (mTOR)-lysosome interaction are associated with the inhibition of lung cancer cell proliferation by a chloroquinoline analog. Mol Pharmacol. 2019;95(1):127–38.", "volume": "95", "year": "2019" }, { "DOI": "10.1248/bpb.b13-00423", "author": "K Togami", "doi-asserted-by": "publisher", "first-page": "1494", "issue": "9", "journal-title": "Biol Pharm Bull", "key": "465_CR30", "unstructured": "Togami K, Chono S, Morimoto K. Subcellular distribution of azithromycin and clarithromycin in rat alveolar macrophages (NR8383) in vitro. Biol Pharm Bull. 2013;36(9):1494–9.", "volume": "36", "year": "2013" }, { "DOI": "10.1016/j.ejps.2010.05.016", "author": "V Munic", "doi-asserted-by": "publisher", "first-page": "86", "issue": "1", "journal-title": "Eur J Pharm Sci", "key": "465_CR31", "unstructured": "Munic V, Kelneric Z, Mikac L, Erakovic HV. Differences in assessment of macrolide interaction with human MDR1 (ABCB1, P-gp) using rhodamine-123 efflux, ATPase activity and cellular accumulation assays. Eur J Pharm Sci. 2010;41(1):86–95.", "volume": "41", "year": "2010" }, { "DOI": "10.1128/AAC.47.7.2283-2292.2003", "author": "C Seral", "doi-asserted-by": "publisher", "first-page": "2283", "issue": "7", "journal-title": "Antimicrob Agents Chemother", "key": "465_CR32", "unstructured": "Seral C, Van Bambeke F, Tulkens PM. Quantitative analysis of gentamicin, azithromycin, telithromycin, ciprofloxacin, moxifloxacin, and oritavancin (LY333328) activities against intracellular Staphylococcus aureus in mouse J774 macrophages. Antimicrob Agents Chemother. 2003;47(7):2283–92.", "volume": "47", "year": "2003" }, { "DOI": "10.1371/journal.pntd.0000236", "author": "A El-Tahtawy", "doi-asserted-by": "publisher", "first-page": "e236", "issue": "5", "journal-title": "PLoS Negl Trop Dis", "key": "465_CR33", "unstructured": "El-Tahtawy A, Glue P, Andrews EN, Mardekian J, Amsden GW, Knirsch CA. The effect of azithromycin on ivermectin pharmacokinetics--a population pharmacokinetic model analysis. PLoS Negl Trop Dis. 2008;2(5):e236.", "volume": "2", "year": "2008" }, { "DOI": "10.1016/S1734-1140(09)70140-9", "author": "XJ He", "doi-asserted-by": "publisher", "first-page": "843", "issue": "5", "journal-title": "Pharmacol Rep", "key": "465_CR34", "unstructured": "He XJ, Zhao LM, Qiu F, Sun YX, Li-Ling J. Influence of ABCB1 gene polymorphisms on the pharmacokinetics of azithromycin among healthy Chinese Han ethnic subjects. Pharmacol Rep. 2009;61(5):843–50.", "volume": "61", "year": "2009" }, { "DOI": "10.1139/cjpp-2019-0569", "doi-asserted-by": "publisher", "key": "465_CR35", "unstructured": "Nazir S, Adnan K, Gul R, Ali G, Saleha S, Khan A. The effect of gender and ABCB1 gene polymorphism on the pharmacokinetics of azithromycin in healthy male and female Pakistani subjects. Can J Physiol Pharmacol. 2020. https://doi.org/10.1139/cjpp-2019-0569." }, { "DOI": "10.1128/AAC.48.3.809-814.2004", "author": "M Sugie", "doi-asserted-by": "publisher", "first-page": "809", "issue": "3", "journal-title": "Antimicrob Agents Chemother", "key": "465_CR36", "unstructured": "Sugie M, Asakura E, Zhao YL, Torita S, Nadai M, Baba K, et al. Possible involvement of the drug transporters P glycoprotein and multidrug resistance-associated protein Mrp2 in disposition of azithromycin. Antimicrob Agents Chemother. 2004;48(3):809–14.", "volume": "48", "year": "2004" }, { "DOI": "10.1172/JCI70430", "author": "P Borst", "doi-asserted-by": "publisher", "first-page": "4131", "issue": "10", "journal-title": "J Clin Invest", "key": "465_CR37", "unstructured": "Borst P, Schinkel AH. P-glycoprotein ABCB1: a major player in drug handling by mammals. J Clin Invest. 2013;123(10):4131–3.", "volume": "123", "year": "2013" }, { "DOI": "10.1016/j.biocel.2011.12.009", "author": "D Fu", "doi-asserted-by": "publisher", "first-page": "461", "issue": "3", "journal-title": "Int J Biochem Cell Biol", "key": "465_CR38", "unstructured": "Fu D, Arias IM. Intracellular trafficking of P-glycoprotein. Int J Biochem Cell Biol. 2012;44(3):461–4.", "volume": "44", "year": "2012" }, { "DOI": "10.1016/j.bbamcr.2015.06.001", "author": "K Katayama", "doi-asserted-by": "publisher", "first-page": "2361", "issue": "10 Pt A", "journal-title": "Biochim Biophys Acta", "key": "465_CR39", "unstructured": "Katayama K, Kapoor K, Ohnuma S, Patel A, Swaim W, Ambudkar IS, et al. Revealing the fate of cell surface human P-glycoprotein (ABCB1): the lysosomal degradation pathway. Biochim Biophys Acta. 2015;1853(10 Pt A):2361–70.", "volume": "1853", "year": "2015" }, { "DOI": "10.1016/j.vascn.2014.08.002", "author": "X Jin", "doi-asserted-by": "publisher", "first-page": "188", "issue": "2", "journal-title": "J Pharmacol Toxicol Methods", "key": "465_CR40", "unstructured": "Jin X, Luong TL, Reese N, Gaona H, Collazo-Velez V, Vuong C, et al. Comparison of MDCK-MDR1 and Caco-2 cell based permeability assays for anti-malarial drug screening and drug investigations. J Pharmacol Toxicol Methods. 2014;70(2):188–94.", "volume": "70", "year": "2014" }, { "DOI": "10.1097/00001813-199607000-00012", "author": "F Tiberghien", "doi-asserted-by": "publisher", "first-page": "568", "issue": "5", "journal-title": "Anti-Cancer Drugs", "key": "465_CR41", "unstructured": "Tiberghien F, Loor F. Ranking of P-glycoprotein substrates and inhibitors by a calcein-AM fluorometry screening assay. Anti-Cancer Drugs. 1996;7(5):568–78.", "volume": "7", "year": "1996" }, { "DOI": "10.1186/1475-2875-13-359", "author": "SR Rijpma", "doi-asserted-by": "publisher", "first-page": "359", "journal-title": "Malar J", "key": "465_CR42", "unstructured": "Rijpma SR, van den Heuvel JJ, van der Velden M, Sauerwein RW, Russel FG, Koenderink JB. Atovaquone and quinine anti-malarials inhibit ATP binding cassette transporter activity. Malar J. 2014;13:359.", "volume": "13", "year": "2014" }, { "DOI": "10.1016/j.ejps.2006.05.009", "author": "R Hayeshi", "doi-asserted-by": "publisher", "first-page": "70", "issue": "1", "journal-title": "Eur J Pharm Sci", "key": "465_CR43", "unstructured": "Hayeshi R, Masimirembwa C, Mukanganyama S, Ungell AL. The potential inhibitory effect of antiparasitic drugs and natural products on P-glycoprotein mediated efflux. Eur J Pharm Sci. 2006;29(1):70–81.", "volume": "29", "year": "2006" }, { "DOI": "10.1111/j.0954-6820.1982.tb01971.x", "author": "I Leden", "doi-asserted-by": "publisher", "first-page": "411", "issue": "5", "journal-title": "Acta medica Scandinavica", "key": "465_CR44", "unstructured": "Leden I. Digoxin-hydroxychloroquine interaction? Acta medica Scandinavica. 1982;211(5):411–2.", "volume": "211", "year": "1982" }, { "DOI": "10.1177/009127000004001226", "author": "GW Amsden", "doi-asserted-by": "crossref", "first-page": "1522", "issue": "12 Pt 2", "journal-title": "J Clin Pharmacol", "key": "465_CR45", "unstructured": "Amsden GW, Nafziger AN, Foulds G, Cabelus LJ. A study of the pharmacokinetics of azithromycin and nelfinavir when coadministered in healthy volunteers. J Clin Pharmacol. 2000;40(12 Pt 2):1522–7.", "volume": "40", "year": "2000" }, { "DOI": "10.1074/jbc.M113.514091", "author": "T Yamagishi", "doi-asserted-by": "publisher", "first-page": "31761", "issue": "44", "journal-title": "J Biol Chem", "key": "465_CR46", "unstructured": "Yamagishi T, Sahni S, Sharp DM, Arvind A, Jansson PJ, Richardson DR. P-glycoprotein mediates drug resistance via a novel mechanism involving lysosomal sequestration. J Biol Chem. 2013;288(44):31761–71.", "volume": "288", "year": "2013" }, { "DOI": "10.1111/tra.12613", "author": "F Wang", "doi-asserted-by": "publisher", "first-page": "918", "issue": "12", "journal-title": "Traffic.", "key": "465_CR47", "unstructured": "Wang F, Gomez-Sintes R, Boya P. Lysosomal membrane permeabilization and cell death. Traffic. 2018;19(12):918–31.", "volume": "19", "year": "2018" }, { "DOI": "10.1124/dmd.112.050054", "author": "F Kazmi", "doi-asserted-by": "publisher", "first-page": "897", "issue": "4", "journal-title": "Drug Metab Dispos", "key": "465_CR48", "unstructured": "Kazmi F, Hensley T, Pope C, Funk RS, Loewen GJ, Buckley DB, et al. Lysosomal sequestration (trapping) of lipophilic amine (cationic amphiphilic) drugs in immortalized human hepatocytes (Fa2N-4 cells). Drug Metab Dispos. 2013;41(4):897–905.", "volume": "41", "year": "2013" }, { "DOI": "10.1016/j.cellimm.2012.09.007", "author": "K Nujic", "doi-asserted-by": "publisher", "first-page": "78", "issue": "1", "journal-title": "Cell Immunol", "key": "465_CR49", "unstructured": "Nujic K, Banjanac M, Munic V, Polancec D, Erakovic HV. Impairment of lysosomal functions by azithromycin and chloroquine contributes to anti-inflammatory phenotype. Cell Immunol. 2012;279(1):78–86.", "volume": "279", "year": "2012" }, { "DOI": "10.3390/molecules22040600", "doi-asserted-by": "publisher", "key": "465_CR50", "unstructured": "Gameiro M, Silva R, Rocha-Pereira C, Carmo H, Carvalho F, Bastos ML, et al. Cellular models and In vitro assays for the screening of modulators of P-gp, MRP1 and BCRP. Molecules. 2017;22(4):2–48. https://doi.org/10.3390/molecules22040600." }, { "DOI": "10.1091/mbc.e02-11-0704", "author": "A Rajagopal", "doi-asserted-by": "publisher", "first-page": "3389", "issue": "8", "journal-title": "Mol Biol Cell", "key": "465_CR51", "unstructured": "Rajagopal A, Simon SM. Subcellular localization and activity of multidrug resistance proteins. Mol Biol Cell. 2003;14(8):3389–99.", "volume": "14", "year": "2003" }, { "DOI": "10.1081/DMR-120001389", "author": "RB Kim", "doi-asserted-by": "publisher", "first-page": "47", "issue": "1–2", "journal-title": "Drug Metab Rev", "key": "465_CR52", "unstructured": "Kim RB. Drugs as P-glycoprotein substrates, inhibitors, and inducers. Drug Metab Rev. 2002;34(1–2):47–54.", "volume": "34", "year": "2002" }, { "DOI": "10.3389/fphar.2019.00749", "author": "P Liu-Kreyche", "doi-asserted-by": "publisher", "first-page": "749", "journal-title": "Front Pharmacol", "key": "465_CR53", "unstructured": "Liu-Kreyche P, Shen H, Marino AM, Iyer RA, Humphreys WG, Lai Y. Lysosomal P-gp-MDR1 confers drug resistance of brentuximab vedotin and its cytotoxic payload monomethyl auristatin E in tumor cells. Front Pharmacol. 2019;10:749.", "volume": "10", "year": "2019" }, { "DOI": "10.1073/pnas.1014641108", "author": "P Kannan", "doi-asserted-by": "publisher", "first-page": "2593", "issue": "6", "journal-title": "Proc Natl Acad Sci U S A", "key": "465_CR54", "unstructured": "Kannan P, Brimacombe KR, Kreisl WC, Liow JS, Zoghbi SS, Telu S, et al. Lysosomal trapping of a radiolabeled substrate of P-glycoprotein as a mechanism for signal amplification in PET. Proc Natl Acad Sci U S A. 2011;108(6):2593–8.", "volume": "108", "year": "2011" }, { "DOI": "10.2147/IDR.S187226", "author": "RJ Davidson", "doi-asserted-by": "publisher", "first-page": "585", "journal-title": "Infect Drug Resist", "key": "465_CR55", "unstructured": "Davidson RJ. In vitro activity and pharmacodynamic/pharmacokinetic parameters of clarithromycin and azithromycin: why they matter in the treatment of respiratory tract infections. Infect Drug Resist. 2019;12:585–96.", "volume": "12", "year": "2019" }, { "DOI": "10.2147/DDDT.S166893", "author": "D Liu", "doi-asserted-by": "publisher", "first-page": "1685", "journal-title": "Drug Des Dev Ther", "key": "465_CR56", "unstructured": "Liu D, Li X, Zhang Y, Kwong JS, Li L, Xu C, et al. Chloroquine and hydroxychloroquine are associated with reduced cardiovascular risk: a systematic review and meta-analysis. Drug Des Dev Ther. 2018;12:1685–95.", "volume": "12", "year": "2018" }, { "DOI": "10.1016/j.ijantimicag.2020.106007", "doi-asserted-by": "publisher", "key": "465_CR57", "unstructured": "Derendorf H. Excessive lysosomal ion-trapping of hydroxychloroquine and azithromycin. Int J Antimicrob Agents. 2020. https://doi.org/10.1016/j.ijantimicag.2020.106007." } ], "reference-count": 57, "references-count": 57, "relation": {}, "resource": { "primary": { "URL": "https://link.springer.com/10.1208/s12248-020-00465-w" } }, "score": 1, "short-title": [], "source": "Crossref", "subject": [], "subtitle": [], "title": "Intracellular ABCB1 as a Possible Mechanism to Explain the Synergistic Effect of Hydroxychloroquine-Azithromycin Combination in COVID-19 Therapy", "type": "journal-article", "update-policy": "http://dx.doi.org/10.1007/springer_crossmark_policy", "volume": "22" }